Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced changes
to its executive leadership team to support its next pivotal phase
of development. Effective immediately, Brad Hauser has been
appointed as President and Chief Executive Officer. Additionally,
Lori Bisson, former President and Chief Executive Officer, has been
appointed Executive Vice Chairman of the Board and will continue to
guide the Company forward on corporate and capital markets
strategies.
Mr. Hauser is a globally renowned medical
technology innovation leader and seasoned executive with more than
20 years of experience building teams that bring unique
energy-based technologies from concept, through design validation,
clinical studies, regulatory approvals, manufacturing, and
commercialization. Over the course of his career, he has been a
visionary for top laser, radiofrequency, sound and cold
technologies treating a broad range of indications from vascular to
adipose tissue to skin. Previously, he was part of the teams that
successfully took three companies through acquisition, Soliton,
Inc., ZELTIQ Aesthetics, and Reliant Technologies, and has been an
officer of four public companies.
“We are extremely grateful for Lori’s
transformational efforts in establishing the solid foundation from
which the Company is now positioned to propel towards our next
phase of growth,” commented Walter Klemp, Executive Chairman of
Autonomix. “We are pleased to welcome Brad to the executive
leadership team and wholeheartedly believe his expertise and proven
track record immediately brings significant value to the
Company.”
Ms. Lori Bisson stated, “Several of our team
members and I have had the pleasure of working with Brad at a prior
company and his leadership style is a perfect fit for the next
phase of Autonomix’s development. In particular, his prior
extensive experience with tissue coagulation and ablation systems
brings a significant value and successful track record, in addition
to his history of blending clinical and regulatory development with
product manufacturing and launch, which truly makes him the ideal
candidate and optimal time for this next step in our Company’s
growth. We are all thrilled to be working with him again.”
Mr. Hauser added, “I couldn’t be more excited by
this opportunity and to team up again with these proven leaders to
fill an important unmet need for patients and their families with
the goal of building significant value for our shareholders. I have
spent the majority of my career working closely with physicians and
partnering with them to advance novel technologies and I believe
that Autonomix has the potential to transform patient outcomes and
revolutionize how diseases involving the nervous system are
diagnosed and treated. The preclinical and initial proof of concept
data are highly compelling, and we will continue to expeditiously
advance our clinical program in order to seek regulatory approvals
globally.”
About Brad Hauser
Mr. Hauser joins Autonomix having most recently
served as the Chief Operating Officer at Beauty Health, a global
category-creating company delivering millions of skin health
experiences every year. While at Beauty Health, he led operations,
marketing, technology, research and development, quality assurance
and regulatory affairs and oversaw product development with a focus
on continuing to advance the HydraFacial delivery systems and
pioneer innovation.
Prior to his appointment at Beauty Health, Mr.
Hauser served as President and Chief Executive Officer at Soliton,
where he led the RESONIC brand from early commercial launch through
acquisition by Allergan Aesthetics, an AbbVie company, for $550M
enterprise value in 2021. Following the acquisition, he served
as President and Chief Executive Officer at Soliton within Allergan
Aesthetics, an AbbVie company until July 2022. Prior to that, he
served in multiple roles at ZELTIQ Aesthetics, Inc. including Vice
President of Product and Clinical Strategy, Vice President of
Research and Development and Senior Vice President of Research and
Development, where he helped build the CoolSculpting franchise from
a $100M to $350M+ global business over 4 years and a sale to
Allergan for $2.4B in 2017. Following the acquisition, his
role increased further to serve as Vice President, R&D and
General Manager for the Coolsculpting and Body Contouring portfolio
at Allergan Pharmaceuticals. Prior to ZELTIQ, Mr. Hauser held
multiple roles in the aesthetic industry, including Executive Vice
President of Commercial Operations for Cutera, Director of
Research and Development at Medicis and Managing Director
of Product and Clinical Marketing at Solta Medical. He
currently sits on the Board of Directors of Candesant Biomedical
and the American Society of Laser Medicine and Surgery, Inc.
(ASLMS). Mr. Hauser holds a Bachelor of Arts in Human Biology from
Stanford University.
Inducement Grant
In connection with Mr. Hauser joining Autonomix,
the Compensation Committee of Autonomix’s Board of Directors
approved the grant of an inducement stock option to be granted on
June 17, 2024, to purchase 900,000 shares of the Company’s common
stock. The option award was granted pursuant to the Nasdaq Rule
5635(c)(4) inducement grant exception as a component of the
individual’s employment compensation and was granted as an
inducement material to his acceptance of employment with
Autonomix.
The option has an exercise price equal to the
closing price of Autonomix’s common stock as reported by the Nasdaq
Capital Market on June 17, 2024. The options have a ten-year term
and vest in four equal annual installments, subject to Mr. Hauser’s
continued service with Autonomix through the applicable vesting
dates.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing technology for pain,
with our first clinical trial focusing on pancreatic cancer, a
condition that causes debilitating pain and is without an effective
solution. Our technology constitutes a platform to address dozens
of indications, including cardiology, hypertension and chronic pain
management, across a wide disease spectrum.
For more information, visit autonomix.com and
connect with the Company on X, LinkedIn, Instagram and
Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Such forward-looking statements can be identified by
the use of words such as “should,” “might,” “may,” “intends,”
“anticipates,” “believes,” “estimates,” “projects,” “forecasts,”
“expects,” “plans,” and “proposes.”
Although Autonomix believes that the
expectations reflected in these forward-looking statements are
based on reasonable assumptions, there are a number of risks and
uncertainties that could cause actual results to differ materially
from such forward-looking statements. You are urged to carefully
review and consider any cautionary statements and other
disclosures, including the statements made under the heading “Risk
Factors” and elsewhere in the Annual Report on Form 10-K filed with
the U.S. Securities and Exchange Commission (“SEC”) on May 31,
2024. Forward-looking statements speak only as of the date of the
document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media ContactJTC Team, LLCJenene
Thomas833-475-8247autonomix@jtcir.com
Grafico Azioni Autonomix Medical (NASDAQ:AMIX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Autonomix Medical (NASDAQ:AMIX)
Storico
Da Dic 2023 a Dic 2024